Call us today 212-583-0100

ENZO Biochem Reports Supporting Laboratory Studies At European Liver Conference

NEW YORK, NY, April 15, 2005 – Enzo Biochem, Inc. (NYSE:ENZ) reported that data from two animal model studies were presented today in Paris, France at the meeting of the European Association for the Study of the Liver. These studies relating to the Company’s proprietary immune regulation platform were presented by Enzo’s scientific collaborators at the Liver Unit at Hadassah University Hospital in Jerusalem, Israel.

 The first presentation focused on the clinical model and immunological effects of various analogues of glycolipids on human hepatocellular carcinoma (HCC) in mice, compared with controls. Animals were followed for tumor size and weight and other immunological parameters, including NKT immune cells. The data show that administration of the glycolipids resulted in marked suppression of HCC and suggest that this anti-tumor effect may be mediated by NKT cells.

 The second presentation dealt with the impact of an inflammatory reaction in one organ on an inflammatory reaction in a second organ, both of which were shown to be mediated by NKT immune cells. Specifically, three groups of mice were studied. In the first two groups of animals, hepatitis and experimental allergic colitis were induced at the same time; in the third group, hepatitis was induced ten days after colitis was induced. Liver damage was evaluated by histology and liver enzymes, and immunological parameters. The results show that when hepatitis was induced in animals already suffering from colitis, the liver damage was worsened, concluding that the severity of an immune response can be modulated by immune signals altering the microenvironment related to another disease process. This immune modulatory effect further supports the notion of an inherent plasticity of NKT regulatory lymphocytes.

About Enzo

Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. The Company’s proprietary labeling and detection products for gene sequencing and genetic analysis are sold to the life sciences market throughout the world. The Company’s therapeutic division is in various stages of clinical evaluation of its proprietary gene medicine for HIV-1 infection and its proprietary immune regulation medicines for hepatitis B and hepatitis C infection and for Crohn’s disease. The Company also holds a patent covering a method and materials for correcting point mutations or small insertions or deletions of genetic material that would allow for editing and correcting certain abnormalities in genes. The Company owns or licenses over 230 patents worldwide. For more information visit our website www.enzo.com.

Except for historical information, the matters discussed in this news release may be considered ”forward looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.